TBK1 and neoplasm: Next, the results shown in Figure 6 indicate that knockdown of TBK1 via its siRNA in MHCC97-H cells enhanced the sensitivity of HCC cells to sorafenib; the antitumor effect of sorafenib significantly increased (the IC50 value of the indicated concentrations of sorafenib reduced from 1.48 ± 0.91 mg/kg to 0.32 ± 0.25 mg/kg and from 1.67 ± 0.33 mg/kg to 0.41 ± 0.10 mg/kg for tumor weights), respectively.